- ACADIA Pharmaceuticals Inc. reported first-quarter 2026 results, with revenue rising to US$268.06 million while net income fell to US$3.64 million, and reaffirmed full-year 2026 revenue guidance of US$1.22 billion to US$1.28 billion, including NUPLAZID and DAYBUE sales ranges.
- Alongside these results, ACADIA reiterated its focus on expanding NUPLAZID and DAYBUE and flagged upcoming phase 2 data for remlifanserin in Alzheimer’s disease psychosis, underscoring management’s emphasis on broadening its central nervous system portfolio.
- We’ll now examine how reaffirmed 2026 revenue guidance and the upcoming remlifanserin phase 2 readout could reshape ACADIA’s investment narrative.
The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.
ACADIA Pharmaceuticals Investment Narrative Recap
To own ACADIA, you have to believe its two commercial products, NUPLAZID and DAYBUE, can support the business while pipeline bets like remlifanserin add new growth legs. The reaffirmed 2026 revenue guidance suggests management still sees the current year as on track, while the upcoming phase 2 readout for remlifanserin remains the key near term catalyst and a major clinical risk that could materially affect sentiment around the stock.
The most relevant recent update here is ACADIA’s decision to reaffirm full year 2026 revenue guidance of US$1.22 billion to US$1.28 billion, including detailed sales ranges for NUPLAZID and DAYBUE. Against a quarter where revenue increased but net income declined, holding guidance steady frames how management views underlying demand for these core drugs ahead of the Alzheimer’s psychosis data, which may be the next big swing factor for expectations.
Yet beneath the reaffirmed guidance, investors should be aware of how dependent ACADIA still is on two products and what happens if...
Read the full narrative on ACADIA Pharmaceuticals (it's free!)
ACADIA Pharmaceuticals' narrative projects $1.6 billion revenue and $286.9 million earnings by 2029.
Uncover how ACADIA Pharmaceuticals' forecasts yield a $31.80 fair value, a 49% upside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were assuming ACADIA could reach about US$1.8 billion in revenue and US$514.8 million in earnings by 2029, which is far more bullish than the baseline view that focuses on execution risk around NUPLAZID, DAYBUE and remlifanserin, and this latest guidance and trial update could easily shift how you weigh those very different stories.
Explore 8 other fair value estimates on ACADIA Pharmaceuticals - why the stock might be worth over 4x more than the current price!
The Verdict Is Yours
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your ACADIA Pharmaceuticals research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free ACADIA Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate ACADIA Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Uncover the next big thing with 27 elite penny stocks that balance risk and reward.
- Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Outshine the giants: these 16 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com